These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 32237123)

  • 1. FHIT
    Da Silva J; Jouida A; Ancel J; Dalstein V; Routhier J; Delepine G; Cutrona J; Jonquet A; Dewolf M; Birembaut P; Deslée G; Polette M; Nawrocki-Raby B
    J Pathol; 2020 Jun; 251(2):187-199. PubMed ID: 32237123
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transcriptomic FHIT
    Brisebarre A; Ancel J; Ponchel T; Loeffler E; Germain A; Dalstein V; Dormoy V; Durlach A; Delepine G; Deslée G; Polette M; Nawrocki-Raby B
    Front Immunol; 2022; 13():1058531. PubMed ID: 36544755
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fhit, a tumor suppressor protein, induces autophagy via 14-3-3τ in non-small cell lung cancer cells.
    Lee TG; Jeong EH; Kim SY; Kim HR; Kim H; Kim CH
    Oncotarget; 2017 May; 8(19):31923-31937. PubMed ID: 28404875
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 5' CpG island methylation of the FHIT gene is correlated with loss of gene expression in lung and breast cancer.
    Zöchbauer-Müller S; Fong KM; Maitra A; Lam S; Geradts J; Ashfaq R; Virmani AK; Milchgrub S; Gazdar AF; Minna JD
    Cancer Res; 2001 May; 61(9):3581-5. PubMed ID: 11325823
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Fhit-mimetic peptide suppresses annexin A4-mediated chemoresistance to paclitaxel in lung cancer cells.
    Gaudio E; Paduano F; Ngankeu A; Ortuso F; Lovat F; Pinton S; D'Agostino S; Zanesi N; Aqeilan RI; Campiglia P; Novellino E; Alcaro S; Croce CM; Trapasso F
    Oncotarget; 2016 May; 7(21):29927-36. PubMed ID: 27166255
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fragile histidine triad protein expression in nonsmall cell lung cancer and correlation with Ki-67 and with p53.
    Mascaux C; Martin B; Verdebout JM; Meert AP; Ninane V; Sculier JP
    Eur Respir J; 2003 May; 21(5):753-8. PubMed ID: 12765416
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased sensitivity to cisplatin in non-small cell lung cancer cell lines after FHIT gene transfer.
    Andriani F; Perego P; Carenini N; Sozzi G; Roz L
    Neoplasia; 2006 Jan; 8(1):9-17. PubMed ID: 16533421
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The methylation status and protein expression of CDH1, p16(INK4A), and fragile histidine triad in nonsmall cell lung carcinoma: epigenetic silencing, clinical features, and prognostic significance.
    Nakata S; Sugio K; Uramoto H; Oyama T; Hanagiri T; Morita M; Yasumoto K
    Cancer; 2006 May; 106(10):2190-9. PubMed ID: 16598757
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fhit regulates EMT targets through an EGFR/Src/ERK/Slug signaling axis in human bronchial cells.
    Joannes A; Grelet S; Duca L; Gilles C; Kileztky C; Dalstein V; Birembaut P; Polette M; Nawrocki-Raby B
    Mol Cancer Res; 2014 May; 12(5):775-83. PubMed ID: 24464917
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synergistic tumor suppression by coexpression of FHIT and p53 coincides with FHIT-mediated MDM2 inactivation and p53 stabilization in human non-small cell lung cancer cells.
    Nishizaki M; Sasaki J; Fang B; Atkinson EN; Minna JD; Roth JA; Ji L
    Cancer Res; 2004 Aug; 64(16):5745-52. PubMed ID: 15313915
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FHIT promoter methylation status, low protein and high mRNA levels in patients with non-small cell lung cancer.
    Czarnecka KH; Migdalska-Sęk M; Domańska D; Pastuszak-Lewandoska D; Dutkowska A; Kordiak J; Nawrot E; Kiszałkiewicz J; Antczak A; Brzeziańska-Lasota E
    Int J Oncol; 2016 Sep; 49(3):1175-84. PubMed ID: 27572663
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FHIT loss confers cisplatin resistance in lung cancer via the AKT/NF-κB/Slug-mediated PUMA reduction.
    Wu DW; Lee MC; Hsu NY; Wu TC; Wu JY; Wang YC; Cheng YW; Chen CY; Lee H
    Oncogene; 2015 May; 34(19):2505-15. PubMed ID: 24998847
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dose-dependent effect of FHIT-inducible expression in Calu-1 lung cancer cell line.
    Cavazzoni A; Petronini PG; Galetti M; Roz L; Andriani F; Carbognani P; Rusca M; Fumarola C; Alfieri R; Sozzi G
    Oncogene; 2004 Nov; 23(52):8439-46. PubMed ID: 15361849
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epigenetic modulation of endogenous tumor suppressor expression in lung cancer xenografts suppresses tumorigenicity.
    Cantor JP; Iliopoulos D; Rao AS; Druck T; Semba S; Han SY; McCorkell KA; Lakshman TV; Collins JE; Wachsberger P; Friedberg JS; Huebner K
    Int J Cancer; 2007 Jan; 120(1):24-31. PubMed ID: 17019711
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fhit regulates invasion of lung tumor cells.
    Joannes A; Bonnomet A; Bindels S; Polette M; Gilles C; Burlet H; Cutrona J; Zahm JM; Birembaut P; Nawrocki-Raby B
    Oncogene; 2010 Feb; 29(8):1203-13. PubMed ID: 19935706
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FHIT loss-induced DNA damage creates optimal APOBEC substrates: Insights into APOBEC-mediated mutagenesis.
    Waters CE; Saldivar JC; Amin ZA; Schrock MS; Huebner K
    Oncotarget; 2015 Feb; 6(5):3409-19. PubMed ID: 25401976
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gasdermin B expression predicts poor clinical outcome in HER2-positive breast cancer.
    Hergueta-Redondo M; Sarrio D; Molina-Crespo Á; Vicario R; Bernadó-Morales C; Martínez L; Rojo-Sebastián A; Serra-Musach J; Mota A; Martínez-Ramírez Á; Castilla MÁ; González-Martin A; Pernas S; Cano A; Cortes J; Nuciforo PG; Peg V; Palacios J; Pujana MÁ; Arribas J; Moreno-Bueno G
    Oncotarget; 2016 Aug; 7(35):56295-56308. PubMed ID: 27462779
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The clinicopathological significance of FHIT hypermethylation in non-small cell lung cancer, a meta-analysis and literature review.
    Yan W; Xu N; Han X; Zhou XM; He B
    Sci Rep; 2016 Jan; 6():19303. PubMed ID: 26796853
    [TBL] [Abstract][Full Text] [Related]  

  • 19. c-Myc suppresses microRNA-29b to promote tumor aggressiveness and poor outcomes in non-small cell lung cancer by targeting FHIT.
    Wu DW; Hsu NY; Wang YC; Lee MC; Cheng YW; Chen CY; Lee H
    Oncogene; 2015 Apr; 34(16):2072-82. PubMed ID: 24909176
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives.
    Mazières J; Peters S; Lepage B; Cortot AB; Barlesi F; Beau-Faller M; Besse B; Blons H; Mansuet-Lupo A; Urban T; Moro-Sibilot D; Dansin E; Chouaid C; Wislez M; Diebold J; Felip E; Rouquette I; Milia JD; Gautschi O
    J Clin Oncol; 2013 Jun; 31(16):1997-2003. PubMed ID: 23610105
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.